Symbol="ACHL"
AssetType="Common Stock"
Name="Achilles Therapeutics PLC ADR"
Description="Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom."
CIK="1830749"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="245 HAMMERSMITH ROAD, LONDON, GB"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="37662300"
EBITDA="-64231000"
PERatio="None"
PEGRatio="None"
BookValue="4.246"
DividendPerShare="0"
DividendYield="0"
EPS="-1.75"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.187"
ReturnOnEquityTTM="-0.35"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.75"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="8.8"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.263"
EVToRevenue="-"
EVToEBITDA="1.59"
Beta="0.947"
num_52WeekHigh="3.25"
num_52WeekLow="0.75"
num_50DayMovingAverage="0.979"
num_200DayMovingAverage="1.075"
SharesOutstanding="40946200"
DividendDate="None"
ExDividendDate="None"
symbol="ACHL"
open="0.89"
high="0.92"
low="0.89"
price="0.92"
volume="32789.00"
latest_trading_day="2023-08-30"
previous_close="0.88"
change="0.04"
change_percent="4.2969%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="49"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="51"
Volume_recent_avg="114225"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.62"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="51"
Aroon_momentum_negative="49"
image_negative_thumbnail_id_1="1102"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0135.jpeg"
image_negative_thumbnail_id_2="1115"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0148.jpeg"
image_neutral_thumbnail_id_1="524"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_neutral_thumbnail_id_2="530"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_positive_thumbnail_id_1="664"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0044.jpeg"
image_positive_thumbnail_id_2="633"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0075.jpeg"
image_professor_thumbnail_id_1="1204"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0038.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
